Boron neutron capture therapy for head and neck cancer: Relevance of nuclear-cytoplasmic volume ratio and anti-tumor effect. -A preliminary report

• Published in: Applied radiation and isotopes Vol. 163; p. 109212
• Main Authors: Aihara, Teruhito, Hiratsuka, Junichi, Kamitani, Nobuhiko, Nishimura, Hirotake, Ono, Koji
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.09.2020
• Subjects: 10B; ABE factor; BNCT; CBE factor; Head and neck cancer; N/C ratio; CBE factor; Head and neck cancer; BNCT; 10B; N/C ratio; ABE factor
• DOI: 10.1016/j.apradiso.2020.109212
• ISSN: 0969-8043; 1872-9800

BNCT is a type of particle beam radiation therapy that utilizes an α particle and 7Li nucleus generated when a thermal neutron is captured by a 10B nucleus involved in the boron compound that has been taken up into tumor tissue selectively. In this report, the relevance of N/C ratio of tumor cell and anti-tumor effect for BNCT clinical cases of head and neck cancer were verified. Examination of pre-irradiated tumor histopathological specimens of 9 BNCT treated head and neck cancer patients (4 CR patients, 5 non-CR patients) was performed. The statistically significant difference between the CR group and the non-CR group was examined for the physical dose was multiplied by the absolute biological effectiveness (ABE) value determined from the patient's tumor specific N/C ratio. Analysis showed the mean tumor dose could not distinguish between CR and non-CR groups. However, the ABE dose could clearly distinguish between the CR group and the non-CR group (p = 0.0250). The N/C ratio of tumor cell can influence the anti-tumor effect of BNCT for HNC. 1.This study is relevance of N/C ratio and anti-tumor effect for BNCT.2.9 patients (4 CR patients, 5 non-CR patients) in our institution who underwent BNCT were analyzed.3.The statistically significant difference between the CR and the non-CR was examined for ABE dose.4.The ABE dose could clearly distinguish between the CR group and the non-CR group (p = 0.0250).5.The ABE dose can influence the anti-tumor effect of BNCT for HNC.